Thal/Dex regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}}Thalidomide-Dexamethasone Regimen ==Overview== {{PAGENAME}} refers to a regimen consisting of thalidomide and dexamethaso...") |
No edit summary |
||
Line 10: | Line 10: | ||
==Regimen== | ==Regimen== | ||
{{chemo|Thal|Thalidomide}} | {{chemo|Thal|Thalidomide}} | ||
{{chemo|Dex|Dexamethasone}} | {{chemo|Dex|Dexamethasone}} | ||
==Indications== | ==Indications== | ||
*[[Multiple myeloma]]<ref name="pmid21901342">{{cite journal| author=Zamagni E, Petrucci A, Tosi P, Tacchetti P, Perrone G, Brioli A et al.| title=Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. | journal=Ann Hematol | year= 2012 | volume= 91 | issue= 3 | pages= 419-26 | pmid=21901342 | doi=10.1007/s00277-011-1320-2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21901342 }} </ref> | *[[Multiple myeloma]]<ref name="pmid21901342">{{cite journal| author=Zamagni E, Petrucci A, Tosi P, Tacchetti P, Perrone G, Brioli A et al.| title=Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. | journal=Ann Hematol | year= 2012 | volume= 91 | issue= 3 | pages= 419-26 | pmid=21901342 | doi=10.1007/s00277-011-1320-2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21901342 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] |
Latest revision as of 15:16, 30 March 2015
WikiDoc Resources for Thal/Dex regimen |
Articles |
---|
Most recent articles on Thal/Dex regimen Most cited articles on Thal/Dex regimen |
Media |
Powerpoint slides on Thal/Dex regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Thal/Dex regimen at Clinical Trials.gov Trial results on Thal/Dex regimen Clinical Trials on Thal/Dex regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Thal/Dex regimen NICE Guidance on Thal/Dex regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Thal/Dex regimen Discussion groups on Thal/Dex regimen Patient Handouts on Thal/Dex regimen Directions to Hospitals Treating Thal/Dex regimen Risk calculators and risk factors for Thal/Dex regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for Thal/Dex regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Thalidomide-Dexamethasone Regimen
Overview
Thal/Dex regimen refers to a regimen consisting of thalidomide and dexamethasone used for the treatment for multiple myeloma.[1][2]
Regimen
ThalThalidomide
DexDexamethasone
Indications
References
- ↑ 1.0 1.1 Zamagni E, Petrucci A, Tosi P, Tacchetti P, Perrone G, Brioli A; et al. (2012). "Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma". Ann Hematol. 91 (3): 419–26. doi:10.1007/s00277-011-1320-2. PMID 21901342.
- ↑ "NCI Thesaurus".